Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PTGX | US
-0.78
-2.26%
Healthcare
Biotechnology
31/03/2024
05/07/2024
33.72
34.14
34.57
33.21
Protagonist Therapeutics Inc. a biopharmaceutical company develops peptide-based drugs for hematology and blood disorders and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300) an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis iron overload and other blood disorders; and JNJ-2113 an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943 an orally delivered gut-restricted alpha 4 beta 7 specific integrin antagonist which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech Inc. Protagonist Therapeutics Inc. was incorporated in 2006 and is headquartered in Newark California.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Operating Margin (> 25%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
50.0%1 month
71.4%3 months
55.5%6 months
57.6%13.64
15.02
4.68
0.00
0.00
-13.67
20.59
-
149.64M
1.98B
1.98B
-
80.92
-
-100.00
41.75
5.11
5.39
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
5.23
Range1M
7.00
Range3M
11.74
Rel. volume
0.49
Price X volume
26.23M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Janux Therapeutics Inc. Common Stock | JANX | Biotechnology | 39.9 | 2.07B | 3.64% | n/a | 3.69% |
Iovance Biotherapeutics Inc | IOVA | Biotechnology | 7.28 | 2.04B | -1.49% | n/a | 12.41% |
Structure Therapeutics Inc. American Depositary Shares | GPCR | Biotechnology | 37.77 | 2.02B | 0.85% | n/a | 1.19% |
Vera Therapeutics Inc. Class A Common Stock | VERA | Biotechnology | 35.63 | 1.95B | 2.12% | n/a | 15.06% |
BEAM THERAPEUTICS INC. | BEAM | Biotechnology | 23.08 | 1.90B | -1.70% | n/a | 18.40% |
Kymera Therapeutics Inc | KYMR | Biotechnology | 30.25 | 1.86B | 0.30% | n/a | 12.24% |
Immunocore Holdings plc | IMCR | Biotechnology | 36.97 | 1.85B | 2.64% | n/a | 131.50% |
Edgewise Therapeutics Inc. | EWTX | Biotechnology | 19.43 | 1.81B | 6.29% | n/a | 0.98% |
Rocket Pharmaceuticals Inc | RCKT | Biotechnology | 19.96 | 1.81B | -0.35% | n/a | 5.88% |
Harmony Biosciences Holdings Inc. | HRMY | Biotechnology | 31.78 | 1.80B | 2.88% | 13.00 | 37.46% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
HNI Corporation | HNI | Building Products & Equipment | 44.43 | 2.10B | -0.96% | 31.70 | 79.49% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 46 | 1.91B | -4.96% | 26.92 | 65.22% |
Janus International Group Inc. | JBI | Building Products & Equipment | 12.25 | 1.79B | -2.31% | 13.29 | 124.30% |
Steelcase Inc | SCS | Building Products & Equipment | 12.82 | 1.46B | -0.93% | 17.05 | 69.98% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 13.45 | 1.31B | -0.37% | n/a | 20.15% |
REV Group Inc | REVG | Recreational Vehicles | 24.74 | 1.28B | -2.06% | 5.86 | 66.74% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.36 | 1.14B | 1.60% | n/a | -628.58% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 17.73 | 799.13M | -2.42% | n/a | 4070.84% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 32.65 | 667.35M | -2.74% | n/a | 4.21% |
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -13.67 | -2.43 | Cheaper |
Ent. to Revenue | 20.59 | 4,101.76 | Cheaper |
PE Ratio | 13.64 | 41.26 | Cheaper |
Price to Book | 4.68 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 55.50 | 76.52 | Lower Risk |
Debt to Equity | 0.00 | 0.51 | Cheaper |
Debt to Assets | 0.00 | 0.24 | Cheaper |
Market Cap | 1.98B | 3.77B | Emerging |